MDxHealth Stock

MDxHealth Current Assets

Delisted·Dec 15, 2023

The Current Assets of MDxHealth (MDXH.BR) as of Aug 12, 2026 is 33.97 M USD. In the previous year, Current Assets was 45.98 M USD — a change of -26.13% (lower).

Current Assets

33.97 MUSD

YoY

-26.13%

Last updated:

Current Assets of MDxHealth is 2026 33.97 M USD. Current Assets of MDxHealth was 2025 45.98 M USD. It decreases by -26.13% lower compared to the previous year.
Access this data via the Eulerpool API

MDxHealth Stock analysis

What does MDxHealth do? MDxHealth SA was founded in 2003 and is a publicly traded company based in Belgium, specializing in the development and marketing of molecular diagnostic tests for cancer diagnosis. The company focuses on developing tests for the diagnosis of prostate, bladder, and kidney cancer, as well as tests for monitoring the progression of these cancer types. The business model of MDxHealth is to develop state-of-the-art molecular diagnostics for cancer medicine and make them accessible to medical professionals and pathologists. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth also provides support to its customers in interpreting test results and choosing the best treatment options for patients. The company has different divisions tailored to the specific needs of patients, doctors, and pathologists. The main divisions are the oncology division and the urology division. In the oncology division, MDxHealth offers various tests for prostate cancer, including the Prognostic Oncotype DX Test used for predicting the progression of prostate cancer. The urology division of MDxHealth focuses on developing tests for bladder cancer and kidney cancer. The key tests in this division include the ConfirmMDx Test used for diagnosing bladder cancer, and the SelectMDx Test used for diagnosing aggressive prostate cancer. MDxHealth also has a significant presence in genomics and personalized medicine. The company partners with the University of Miami Miller School of Medicine to research and improve the application of genetic tests in cancer diagnosis and treatment. MDxHealth also collaborates closely with other leading research institutions and cancer centers to drive innovation in molecular diagnostics. Overall, MDxHealth offers a wide range of molecular diagnostic tests for cancer diagnosis and monitoring. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth is a key player in the field of molecular diagnostics and has the potential to improve the lives of cancer patients worldwide. MDxHealth is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MDxHealth stock

Current Assets of MDxHealth is 33.97 M USD in 2026.

Current Assets of MDxHealth changed from 45.98 M USD to 33.97 M USD, representing a -26.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets MDxHealth since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's MDxHealth historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — MDxHealth

All Key Metrics — MDxHealth